Patients with liver disease frequently develop coagulopathy, and fresh frozen plasma is traditionally used for correction of coagulopathy to manage and prevent bleeding. Prothrombin complex concentrates (PCCs) offer an attractive alternative because they are more readily available and avoid large-volume transfusion. This retrospective, singlecenter study reviewed clinical use of PCC in patients with acute/chronic liver disease. A total of 105 patients with 194 episodes of PCC administration were reviewed. Data pertaining to indication, dosing, effectiveness, and safety were collected. The effect of PCC on coagulation was analyzed in patients for whom coagulation results were available 7 hours before and after PCC. Data on thromboembolic events and mortality within 4 weeks of PCC administration were captured. Most patients (77%) had chronic liver disease; the remainder had acute liver failure. L iver disease is the fifth most common cause of death in the United Kingdom.
hypertension and coagulopathy or need an invasive procedure (e.g., diagnostic workup or therapeutic surgery). (2, 3) Liver failure encompasses a wide spectrum of liver diseases, ranging from progressive chronic disease to de novo acute liver failure. It is increasingly acknowledged that patients with chronic liver disease have dysregu lated coagulation with an increased risk of thrombo sis as well as diminished hemostatic reserve, meaning they are likely to decompensate early during bleed ing.
(46) Similar hemostatic abnormalities are observed in acute liver failure. (7) Regardless of the nature of the disease, hemostatic derangements are common and include decreased plasma levels of procoagulants and anticoagulants due to decreased synthesis and a low platelet count/impaired platelet function. (8, 9) As a result, patients with liver disease undergoing surgery may be at risk of thrombosis as well as bleeding. (7, 10, 11) Spontaneous bleeding is uncommon and infrequently observed in clinical practice, and bleeding risk is pri marily procedure related.
In the context of bleeding, early replenishment of coagulation factors may be required due to the dimin ished reserve. Patients with liver disease who have abnormal prothrombin time (PT) and elevated inter national normalized ratio (INR) may receive replace ment therapy with fresh frozen plasma (FFP), either prophylactically to prevent bleeding in the context of procedures or for bleeding related to underlying liver disease. Where clinically indicated, FFP is the current standard of care for the management of coagulopa thy to treat active bleeding or for prophylaxis before an invasive procedure. (1215) Typically, an FFP dose of 15 mL/kg is suggested for correction of coagulopa thy (16) ; however, patients with liver disease may not tolerate this volume, which creates a significant barrier to effective treatment with FFP.
In the United Kingdom and Europe, prothrombin complex concentrates (PCCs) have a broad license for treatment and prophylaxis of bleeding in acquired deficiency of PCC factors. (17) PCCs consist of non activated vitamin K-dependent coagulation factors and anticoagulant proteins C and S and have demon strated superiority over FFP in the reversal of acquired coagulation factor deficiency induced by vitamin K antagonists.
(1820) Indeed, guidelines advocate the use of PCCs to reverse the effects of vitamin K antag onists over FFP (21) because they are concentrated, ensure consistent correction, and reduce the risk of fluid overload. (22) Because vitamin K-dependent clot ting factors are also decreased in liver disease, studies have suggested a potential role for PCCs in patients with coagulopathy related to liver disease.
(2326) PCCs in this scenario have the same advantages over FFP, particularly in actively bleeding patients. (22) Because the risk of thromboembolic complications is a concern with the clinical use of PCCs (particularly when high or repeated doses are given), (27, 28) PCC administra tion in bleeding patients is ideally guided by throm boelastogram and/or rotational thromboelastometry in addition to PT/INR; this needs to be preceded by adequate replenishment of fibrinogen. (27) In our institution, FFP has over recent years been replaced by PCCs for managing the coagulopathy of liver disease for certain clinical scenarios. Currently, two types of PCC preparation are widely available worldwide; these contain either three factors (II, IX, and X) or four factors (II, VII, IX, and X). In this retrospective, singlecenter audit/service evaluation, we describe our experience of fourfactor PCC use in patients with acute and chronic liver disease. Our aim was to evaluate the indications for PCC use and the correction of PT/INR at each administration. In addition, the coadministration of other products and aRtiCle inFoRmation: safety outcomes, including the presence of thrombotic complications, was assessed.
Methods

stuDy Design
This was a retrospective, singlecenter audit/service evaluation of the use of PCCs in patients with acute or chronic liver disease. All data were collected at the Royal Free Hospital, London, United Kingdom. Ethical review was not required because the study was considered to represent an audit of routine clinical practice with the aim of improving patient care.
All use of PCCs was recorded at the time of treat ment on a form capturing patient details, indica tion for use, date and time of administration, dose, and baseline coagulation test results. All patients had received PCCs between January 2008 and June 2012. Data were transferred to a structured form and ano nymized at the earliest opportunity.
Medical notes were reviewed, and the following data were collected: patient demographics; details of the underlying liver disease, including etiology and severity; risk factors for cardiovascular and cerebro vascular disease (e.g., hypertension, diabetes mellitus, smoking, hypercholesterolemia); and the presence of any cardiovascular or cerebrovascular disease (e.g., ischemic heart disease, coronary artery bypass graft, transient ischemic attacks, cerebrovascular accidents). History of venous thromboembolic disorders, such as peripheral deep vein thrombosis, pulmonary embo lism, and thrombosis of portal and other visceral veins, was also documented.
Additional 
stuDy outComes
The primary outcomes of the study were the cate gorization of indications for PCC administration and the ability of PCC to correct PT/INR at each admin istration and potential relation to the dose adminis tered. The secondary outcome was the assessment of coadministration of other hemostatic products. Because some patients received more than one dose of PCC, safety outcomes, including thrombotic compli cations and mortality, were reported for each patient.
tReatment pRoDuCts, Dosing, anD monitoRing
The PCCs administered were Beriplex P/N (CSL Behring, Marburg, Germany) and, during 2008, Octaplex (Octapharma, Lachen, Switzerland). Beriplex and Octoplex are 4factor PCCs that con tain coagulation factors II, VII, IX, and X along with proteins C, S, and Z with variable amounts of hep arin. (17, 29) These products are licensed in the United Kingdom and Europe for treatment and perioperative prophylaxis of bleeding related to acquired deficien cies of vitamin K-dependent coagulation factors, and for treatment and perioperative prophylaxis of bleed ing in congenital deficiency of any of the vitamin Kdependent coagulation factors. (17, 29) Dosing of PCC was guided by coagulation test results and underlying thrombotic history. Based on experience with PCC in warfarin reversal, doses of 20 IU/kg to 25 IU/kg were administered to patients with INR less than 4.0, and 30 IU/kg for patients with INR greater than 4.0. (30) The actual dose administered was rounded to the nearest whole number of PCC vials. During prolonged inpatient stays, repeat doses were generally given over several days, or occasionally twice a day; in such instances, the INR was often used as a guide for repeat dosing. In eight instances, repeat doses were given within 7 hours. Clinicians were encouraged to send blood samples for coagulation testing just before administration of PCC and 15 to 30 minutes after administration. In keeping with the halflife of fac tor VII and its effect on the INR, only samples taken within 7 hours before and 7 hours after PCC admin istration were included for the analyses reported here.
In accordance with hospital policy, fibrinogen con centrate or cryoprecipitate was administered when plasma fibrinogen levels were less than or equal to 2 g/L in actively bleeding patients and less than or equal to 1.0 g/L to 1.5 g/L in patients scheduled to undergo a surgical procedure.
statistiCal analyses
Statistical analyses comparing results obtained before versus after each PCC administration were performed using the Wilcoxon matchedpairs test, except for episodes with INR less than or equal to 1.5, in which the McNemar test was used. Analyses were categorized per episode according to whether fibrinogen and/or cryoprecipitate was administered. Episodes that required coadministration of rFVIIa (n = 4) were excluded from these analyses.
Results
patient DemogRapHiCs anD CliniCal CHaRaCteRistiCs at aDmission
Initially, 107 consecutive patients with liver dis ease receiving 197 PCC treatments were included; 2 of these patients, both of whom underwent hepatec tomy, were excluded because underlying liver disease could not be confirmed. The final analysis therefore included 194 PCC administration events in 105 patients. Demographics of the patient population and the underlying etiology and severity of liver disease at admission are presented in Table 1 . Most of the patients included had severe liver disease and coagu lation abnormalities. Of the 81 patients with chronic liver disease, 18 were admitted for elective orthotopic liver transplantation, and 12 had hepatocellular car cinoma. Of the 24 patients with acute liver failure, 6 required liver transplantation. Table 2 presents the indications for initial admis sion along with the severity of the liver disease and selected laboratory test results for each indication. Many patients appeared to have severe coagulopa thy: 45% had an INR greater than 2.0, and 36% had fibrinogen levels of 1.5 g/L or less. Abbreviations: OLT, orthotopic liver transplantation.
pCC aDministRation, tRansFusion oF BlooD Components, anD otHeR HemostatiC tHeRapiesepisoDe-leVel analysis
Of the 194 PCC administration episodes assessed, 93 were for preprocedure prophylaxis (48%) and 101 (active: n = 81; recent: n = 20) for bleeding (52%). Details of PCC and concurrent hemostatic therapy in relation to preprocedure prophylaxis and bleeding (recent and active) are provided in 
Dose oF pCC peR aDministRation anD CoaDministRation oF otHeR HemostatiC tHeRapies
Dose of PCC per administration is shown in Figure 1 . The most commonly administered dose (30% of all episodes) was 1,500 IU; accordingly, the median dose was 1,500 IU (interquartile range [IQR]: 1,0002,000 IU). With respect to body weight, the most common dose range was 21 IU/kg to 25 IU/kg, in keeping with the recommended dose for warfarin reversal in patients with INR 2.03.9. The median dose was 22 IU/kg (IQR: 1629 IU/kg). Sixtysix percent of patients received a single dose of PCC, 12% received two doses, 9% received three doses, 8% received four doses, and 6% received more than four doses.
In the overall population, in addition to PCC, 35% of patients received fibrinogen concentrate, and 29% received cryoprecipitate. Fibrinogen was most fre quently administered at a dose of 1 to 2 g (46% of treatment episodes), although nearly as many doses *For 1 patient, the specific procedure is not available. † Supporting Table S1 provides details of therapy stratified by surgical procedure (central venous pressure, transjugular intrahepatic portosystemic shunt, hepatic embolization, paracentesis, thoracocentesis and tracheostomy, intracranial pressure bolt, orthotopic liver transplantation, other). ‡ Supporting Table S2 provides details of therapy stratified by bleeding category (gastrointestinal bleeding-variceal, gastrointestinal bleeding-nonvariceal, linerelated/drainrelated and bleeding tumor, orthotopic liver transplantation, intracranial, trauma, other). § Other hemostatic agents used for preprocedure prophylaxis, active bleeding, and recent bleeding included vitamin K (37%, 33%, and 30%, respectively), tranexamic acid (5%, 14%, and 0%, respectively), and recombinant activated factor VII (2%, 2%, and 0%, respectively). Abbreviations: FFP, fresh frozen plasma; PCC, prothrombin complex concentrate. of 3 to 4 g were given (44% of episodes; Fig. 1 ). The median dose of fibrinogen concentrate was 3.0 g (IQR: 2.03.0 g). Among patients receiving cryoprecipitate, the median dose was 2.0 units (IQR: 1.02.0 U).
pCCs anD Coagulation test Results By episoDe
Coagulation results were available within 7 hours before PCC administration in 71% of episodes and within 7 hours after PCC administration in 65% of episodes; in this group of patients with postadmin istration coagulation test results available, all dose ranges of PCC were included. No differences were found between patients receiving PCC for bleeding or prophylactically with respect to hemoglobin, PT, INR, activated partial thromboplastin time, or plasma fibrinogen levels, except for higher hemoglobin in patients treated prophylactically. PCC therapy produced statistically significant reductions in PT and INR, regardless of the admin istration of fibrinogen concentrate/cryoprecipitate ( Table 4) . The percentage of patients with INR less than or equal to 1.5 increased significantly in response to PCC therapy. Nonsignificant trends toward short ened activated partial thromboplastin time values were observed. A significant increase in plasma fibrinogen was seen in patients who received fibrinogen concen trate or cryoprecipitate but not in patients who did not receive these products. No significant change in hemoglobin was observed in either of the two groups.
tHRomBosis RisK FaCtoRs anD tHRomBotiC CompliCationspatient-leVel analysis
Because thrombosis is a potential complication with the use of PCC, the prevalence of thrombotic risk factors was assessed. Hypertension and diabetes were prevalent in 23% and 19% of patients, respec tively. Eight percent of patients had previously under gone coronary artery bypass graft or coronary artery stenting or had a previous myocardial infarction; 4% had a previous transient ischemic attack/stroke; and 8% had other heart disease (e.g., atrial fibrillation, congestive cardiac failure). Four patients had previ ous deep vein thrombosis and pulmonary embolism, and 1 patient had Budd-Chiari syndrome. Portal vein thrombosis had occurred in 10 patients, and superior mesenteric vein thrombosis had previously affected 1 patient.
No cardiovascular adverse events or strokes were recorded during the 4week followup period after administration of PCC. Three patients (3%) presented with venous thromboembolic events. The first patient was admitted for acute liver failure due to paracetamol overdose and underwent liver transplantation. A lack of blood flow in the hepatic artery following the trans plant procedure was complicated by massive intraab dominal bleeding, requiring further exploration, for which the patient was treated with PCC. Seven days after transplant, an angiogram revealed hepatic artery thrombosis, and a second transplant was required. The second patient was found to have a small, bilateral pulmonary embolism during a computed tomography scan of the chest, which was undertaken for another indication 15 days after PCC treatment. In the third patient, elective orthotopic liver transplantation was complicated by pericardial breach and massive transfusion; PCC was administered during the trans plant procedure. One week after PCC treatment, the patient was found to have nonocclusive portal vein thrombosis.
moRtality
Fortysix patients died, giving an overall mortal ity rate of 44% (Supporting Table S3 ). None of the deaths were considered related to the administra tion of PCC. Of the 46 deaths, 11 (24%) occurred within 24 hours of the last PCC administration, and 33 (72%) occurred more than 24 hours after the last PCC treatment but before patients were discharged from the hospital. As expected, higher mortality rates were observed in patients admitted for decompensated liver disease and in those with ChildPugh grade C.
Discussion
This large case series reports on the use of PCC to manage coagulopathy in patients with liver dis ease who have bleeding and are undergoing surgical procedures. Approximately threequarters of patients who received PCC had chronic liver disease, and the remainder had acute liver failure. Similar numbers of patients received PCC treatment for preprocedure prophylaxis and for active or recent bleeding. PCC treatment was associated with a statistically signif icant correction of INR. Many patients with severe coagulopathy had hypofibrinogenemia, necessitating fibrinogen supplementation in addition to PCC ther apy. FFP use was lower when PCCs were used pro phylactically, suggesting that PCC served as an FFP substitute; the need for concomitant platelet trans fusion in onethird of treatment episodes reflects the severity of the underlying coagulopathy. Reported use of hemostatic agents in patients with liver disease is often limited to case series and expert opinions. An early study in patients with liver disease showed that large volumes of FFP are required to produce a significant improvement in PT. (31) It was subsequently shown that the rise in coagulation factor levels following FFP therapy is variable; levels peaked at the end of treatment and returned to baseline at 24 hours. (32) Administration of higher doses of FFP (≥6 units) may increase its effectiveness, but such doses are rarely used and have been shown to bring PT to within 3 seconds of the normal range in only 20% of patients. (33) Considering the limitations of FFP, our study expands on findings from smaller studies investigat ing PCCs to prevent or treat bleeding in patients with liver disease. In an early study of 22 patients requiring hemostatic treatment for bleeding or before an urgent surgical procedure, PCC (median dose of 25.7 IU/kg) was judged to have a "very good" clinical effect in 76% of the patients. (23) Markers of coagulation activation, including prothrombin fragment 1 + 2, thrombinantithrombin complex, and Ddimers, were elevated after the administration of PCC, but no thromboem bolic complications were reported. (23) One large case series has described the use of PCC and/or fibrinogen in 156 patients (out of a cohort of 266) following liver transplantation; no significant difference was observed in thrombotic, thromboem bolic, or ischemic adverse events between patients who received PCC and/or fibrinogen and those who did not. (34) An ex vivo study of PCC conducted using blood samples from liver transplant recipients showed that PCC was more effective than FFP in increasing thrombin generation. (25) Similarly, in a study testing the effects of in vitro addition of hemostatic agents using thrombin generation tests, FFP and rFVIIa only modestly increased thrombin generation in patients with compensated and acutely decompensated cir rhosis, whereas PCC increased thrombin generation 2fold to 4fold in these patients and approximately 2fold in healthy individuals. (35) In a clinical study conducted across a range of settings, which included a small cohort of patients with liver disease, PCC therapy was associated with a trend toward a reduc tion in INR. (24) In a more recent study of 31 patients with liver disease, PCC was shown to achieve INR less than or equal to 1.5 in 6 patients (19%), whereas hemostasis was achieved in the same number. (26) These percentages were significantly lower than those seen in patients without liver disease (82% and 43%, respectively). (26) The investigators suggested this was a result of underdosing; however, this study reported a similar median dose to our study.
The contribution of coagulopathy to bleeding risk was recognized as early as the 1950s (36, 37) ; current guidelines consider bleeding risk and coagulopathy in their recommendations for management of patients with liver disease. (3, 38) In a nationwide audit of percu taneous liver biopsy in England and Wales, bleeding risk with liver biopsy was approximately 3.3% with INR values of 1.31.5 but dramatically increased to 7.1% with INR greater than 1.5. (39) In our cohort of patients, we found a significant decrease in INR following PCC therapy, with INR less than or equal to 1.5 in a substantial proportion of patients (25% of patients with coadministration of fibrinogen or cryo precipitate; 22% of patients with no coadministration; Table 4 ). However, INR was not decreased below 1.5 in all patients; this could be related to the relatively low doses of PCC and the fact that most samples for measuring INR were taken some time after PCC therapy. Among patients who received fibrinogen concentrate or cryoprecipitate in addition to PCC, a statistically significant increase in the plasma fibrin ogen concentration was seen. An important advan tage of using coagulation factor concentrates to treat coagulopathy is that the levels of specific coagulation factors can be increased reliably in a short time frame.
As with most treatments, dosing affects the safety profile of PCC. The median dose in our study was 22 IU/kg, which is below the lowest recommended dose for anticoagulation reversal (25 IU/kg). (17) It is also slightly lower than the median dose used in the study of PCCs in liver disease by Lorenz et al. (23) The safety outcomes in this study appear to support the relatively conservative dosing strategy currently used at our institute. However, further data are needed to confirm the optimum approach to PCC dosing in this setting.
Thromboembolic complications are an important consideration when using PCCs and particularly so in patients with liver disease who are likely to have low levels of coagulation inhibitors. In the present study, thromboembolic complications occurred in 3% of patients, which was lower than expected for this patient population in the absence of PCC therapy. For example, in a review of orthotopic liver transplantation complications, portal vein thrombosis was reported to occur in 4.9%10.6% of patients and deep vein throm bosis in 3.5%8.6% of patients. (40) A review of rFVIIa studies reported an odds ratio for arterial thromboem bolic events of 2.19 (95% confidence interval: 0.89 5.42) in patients with advanced liver disease. (41) Thus, our data suggest a more favorable safety profile with PCC than rFVIIa.
The high mortality rate reported in our study was considered not to be related to PCC therapy. Instead, high mortality may be more inherent to the multiple comorbidities associated with liver disease. This find ing is consistent with a recent study comparing PCC use in patients with and without liver disease; mortal ity rate in patients with liver disease was 51.6% com pared with 18.5% in patients without liver disease. (26) Strengths of our study include the realworld set ting and the large sample size given the clinical set ting; we also believe the patients at our center are typical of a UK tertiary center with a liver transplant unit. This means the findings should be applicable to clinical practice. Although it is possible that there was a selection bias regarding the use of PCCs (i.e., patients with more severe coagulopathy are selected for PCC therapy), such bias may be expected in clini cal practice, reinforcing the applicability of our results to everyday practice.
Limitations of our study include the retrospective study design with no control groups; this prevented any comparison against patients who did not receive PCC. There was also substantial heterogeneity across the patients in the study. Because bleeding sites and urgency of reversal varied between patients, hemo static interventions were multifactorial; therefore, there was no objective clinical assessment. Moreover, more than half of the study population received PCC for prophylaxis; however, the benefits of prophylactic correction in this population are not clear. It should also be noted that other hemostatic agents were used in addition to PCC for a large proportion of patients in our study, which may not be representative of prac tices at other centers and limits interpretation of the data in terms of PCC use.
Although a significant effect on INR was observed in our study, INR was reported only for 65% of epi sodes. Furthermore, the clinical significance of this finding is unclear given recent findings suggesting "rebalanced hemostasis" in patients with liver dis ease in which both procoagulants and anticoagulants are reduced. (42) This rebalancing means that, despite PT prolongation, thrombin generation may in fact be normal, as demonstrated in thrombin generation assays. (11, 42) Conventional coagulation tests, includ ing PT and INR, measure levels of procoagulants but not levels of anticoagulants; as a consequence, PT and INR are not reliable indicators of overall coagulation status in patients with liver disease, with the threshold values for increased risk of thrombosis and bleeding poorly defined. Global assays, such as the thrombin generation assay, evaluate the overall balance of coag ulation factors (43) ; however, the physiological relevance of the modified assay with regard to bleeding tendency has not been demonstrated in studies of invasive pro cedures or animal models. Furthermore, the assay has not been validated for prediction of bleeding risk and is not routinely available to guide hemostatic treat ment. Despite their limitations, in the absence of a validated global assay, clinical decisions are still made based on conventional PT and INR testing. (43) Future studies of PCC for this patient popula tion need to be prospective and include a comparator group, objective measures of hemostasis (e.g., blood loss), and comprehensive evaluation of coagulation. In addition, the use of additional hemostatic ther apy could be assessed-preferably with a coagulation management algorithm to ensure consistency.
In conclusion, our study showed that PCCs were used more frequently in patients with chronic liver disease than those with acute liver failure. Similar numbers of patients received PCC treatment for preprocedure prophylaxis and active/recent bleed ing. PCC therapy was effective in improving coag ulation test results, with no evidence of an increased risk of thromboembolism. These findings highlight the need for further assessment of the potential role for PCC as hemostatic therapy in patients with liver disease.
